- Home
- TRC vs MNPR Comparison
TRC vs MNPR Comparison
Compare TRC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- MNPR
- Stock Information
- Founded
- TRC 1843
- MNPR 2014
- Country
- TRC United States
- MNPR United States
- Employees
- TRC 88
- MNPR N/A
- Industry
- TRC Real Estate
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- MNPR Health Care
- Exchange
- TRC Nasdaq
- MNPR Nasdaq
- Market Cap
- TRC 419.0M
- MNPR 531.6M
- IPO Year
- TRC N/A
- MNPR 2019
- Fundamental
- Price
- TRC $15.97
- MNPR $82.50
- Analyst Decision
- TRC
- MNPR Strong Buy
- Analyst Count
- TRC 0
- MNPR 12
- Target Price
- TRC N/A
- MNPR $96.64
- AVG Volume (30 Days)
- TRC 85.5K
- MNPR 102.1K
- Earning Date
- TRC 11-06-2025
- MNPR 11-10-2025
- Dividend Yield
- TRC N/A
- MNPR N/A
- EPS Growth
- TRC N/A
- MNPR N/A
- EPS
- TRC N/A
- MNPR N/A
- Revenue
- TRC $45,307,000.00
- MNPR N/A
- Revenue This Year
- TRC N/A
- MNPR N/A
- Revenue Next Year
- TRC N/A
- MNPR N/A
- P/E Ratio
- TRC N/A
- MNPR N/A
- Revenue Growth
- TRC 14.79
- MNPR N/A
- 52 Week Low
- TRC $14.71
- MNPR $14.88
- 52 Week High
- TRC $19.39
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- TRC 49.51
- MNPR 52.39
- Support Level
- TRC $15.44
- MNPR $77.00
- Resistance Level
- TRC $16.00
- MNPR $86.14
- Average True Range (ATR)
- TRC 0.34
- MNPR 6.00
- MACD
- TRC 0.04
- MNPR -1.21
- Stochastic Oscillator
- TRC 56.99
- MNPR 60.62
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.